<?xml version="1.0" encoding="UTF-8"?>
<feed xmlns="http://www.w3.org/2005/Atom">
  <id>https://recalls.watch/feed/substance-duloxetine.xml</id>
  <title>Recalls Watch: Duloxetine</title>
  <link rel="self" href="https://recalls.watch/feed/substance-duloxetine.xml"/>
  <link href="https://recalls.watch/alerts/"/>
  <updated>2026-07-01T00:00:00Z</updated>
  <entry>
    <id>https://recalls.watch/recall/fda/99269/</id>
    <title>Direct Rx: DULOXETINE D/R</title>
    <link href="https://recalls.watch/recall/fda/99269/"/>
    <updated>2026-07-01T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit</summary>
  </entry>
  <entry>
    <id>https://recalls.watch/recall/fda/99108/</id>
    <title>Breckenridge Pharmaceutical, Inc.: Duloxetine Delayed-Release Capsules and 1 more</title>
    <link href="https://recalls.watch/recall/fda/99108/"/>
    <updated>2026-06-17T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit</summary>
  </entry>
  <entry>
    <id>https://recalls.watch/recall/fda/99019/</id>
    <title>Asclemed USA Inc.: Duloxetine DR Capsules</title>
    <link href="https://recalls.watch/recall/fda/99019/"/>
    <updated>2026-06-10T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: CGMP Deviations; presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-nitroso-duloxetine, above the FDA acceptable intake limit.</summary>
  </entry>
  <entry>
    <id>https://recalls.watch/recall/fda/98803/</id>
    <title>Breckenridge Pharmaceutical, Inc.: Duloxetine Delayed-Release Capsules USP</title>
    <link href="https://recalls.watch/recall/fda/98803/"/>
    <updated>2026-05-13T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit</summary>
  </entry>
  <entry>
    <id>https://recalls.watch/recall/fda/98785/</id>
    <title>Ajanta Pharma Ltd.: Duloxetine Delayed-Release Capsules and 2 more</title>
    <link href="https://recalls.watch/recall/fda/98785/"/>
    <updated>2026-05-13T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: CGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA recommended limit of 0.83 ppm, identified at the 12-month and 18-month long-term stability intervals.</summary>
  </entry>
  <entry>
    <id>https://recalls.watch/recall/fda/98034/</id>
    <title>Breckenridge Pharmaceutical, Inc.: Duloxetine Delayed-Release Capsules and 1 more</title>
    <link href="https://recalls.watch/recall/fda/98034/"/>
    <updated>2025-12-10T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit</summary>
  </entry>
  <entry>
    <id>https://recalls.watch/recall/fda/97797/</id>
    <title>Breckenridge Pharmaceutical, Inc.: Duloxetine Delayed-Release Capsules</title>
    <link href="https://recalls.watch/recall/fda/97797/"/>
    <updated>2025-11-05T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: CGMP Deviations: N-nitroso-duloxetine impurity above the safety assessment limit of 12.5ppm.</summary>
  </entry>
  <entry>
    <id>https://recalls.watch/recall/fda/97425/</id>
    <title>Breckenridge Pharmaceutical, Inc.: Duloxetine Delayed-Release Capsules</title>
    <link href="https://recalls.watch/recall/fda/97425/"/>
    <updated>2025-09-17T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: CGMP deviations: N-nitroso-duloxetine impurity above the proposed interim limit.</summary>
  </entry>
  <entry>
    <id>https://recalls.watch/recall/fda/97336/</id>
    <title>Breckenridge Pharmaceutical, Inc.: Duloxetine Delayed-Release Capsules</title>
    <link href="https://recalls.watch/recall/fda/97336/"/>
    <updated>2025-08-20T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.</summary>
  </entry>
  <entry>
    <id>https://recalls.watch/recall/fda/97276/</id>
    <title>Breckenridge Pharmaceutical, Inc.: Duloxetine Delayed-Release Capsules</title>
    <link href="https://recalls.watch/recall/fda/97276/"/>
    <updated>2025-08-13T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: CGMP Deviations: Presence of N-nitroso-duloxetine impurity above safety assessment limit</summary>
  </entry>
  <entry>
    <id>https://recalls.watch/recall/fda/97251/</id>
    <title>Direct Rx: Duloxetine D/R and 1 more</title>
    <link href="https://recalls.watch/recall/fda/97251/"/>
    <updated>2025-08-13T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.</summary>
  </entry>
  <entry>
    <id>https://recalls.watch/recall/fda/97179/</id>
    <title>Breckenridge Pharmaceutical, Inc.: Duloxetine Delayed-Release Capsules</title>
    <link href="https://recalls.watch/recall/fda/97179/"/>
    <updated>2025-07-16T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit</summary>
  </entry>
  <entry>
    <id>https://recalls.watch/recall/fda/96707/</id>
    <title>Breckenridge Pharmaceutical, Inc: Duloxetine Delayed-Release Capsules USP and 1 more</title>
    <link href="https://recalls.watch/recall/fda/96707/"/>
    <updated>2025-04-30T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.</summary>
  </entry>
  <entry>
    <id>https://recalls.watch/recall/fda/96582/</id>
    <title>Breckenridge Pharmaceutical, Inc.: Duloxetine Delayed-Release Capsules</title>
    <link href="https://recalls.watch/recall/fda/96582/"/>
    <updated>2025-04-09T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: CGMP Deviations: presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-nitroso-duloxetine, above the recommended interim limit.</summary>
  </entry>
  <entry>
    <id>https://recalls.watch/recall/fda/96427/</id>
    <title>Rising Pharma Holding, Inc.: Duloxetine Delayed-Release Capsules</title>
    <link href="https://recalls.watch/recall/fda/96427/"/>
    <updated>2025-03-26T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: CGMP Deviations: Presence of N-nitroso-duloxetine impurity above recommended interim limit.</summary>
  </entry>
  <entry>
    <id>https://recalls.watch/recall/fda/96380/</id>
    <title>Breckenridge Pharmaceutical, Inc.: Duloxetine Delayed-Release Capsules and 2 more</title>
    <link href="https://recalls.watch/recall/fda/96380/"/>
    <updated>2025-03-19T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.</summary>
  </entry>
  <entry>
    <id>https://recalls.watch/recall/fda/96105/</id>
    <title>The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories: Duloxetine Delayed-Release Capsules USP</title>
    <link href="https://recalls.watch/recall/fda/96105/"/>
    <updated>2025-02-05T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: CGMP Deviations: presence of Nitrosamine Drug Substances Related Impurity (NDSRI), N-Nitroso-Duloxetine above the FDA recommended acceptable intake limit</summary>
  </entry>
  <entry>
    <id>https://recalls.watch/recall/fda/96074/</id>
    <title>Rising Pharma Holding, Inc.: Duloxetine Delayed-Release Capsules USP 30 mg and 2 more</title>
    <link href="https://recalls.watch/recall/fda/96074/"/>
    <updated>2025-01-15T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: CGMP Deviations; Presence of N-nitroso-duloxetine impurity above recommended interim limit.</summary>
  </entry>
  <entry>
    <id>https://recalls.watch/recall/fda/95953/</id>
    <title>Amerisource Health Services LLC: Duloxetine Delayed-Release Capsules USP and 3 more</title>
    <link href="https://recalls.watch/recall/fda/95953/"/>
    <updated>2025-01-01T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: CGMP Deviations: Presence of N-nitroso-duloxetine impurity above the recommended interim limit.</summary>
  </entry>
  <entry>
    <id>https://recalls.watch/recall/fda/95922/</id>
    <title>PD-Rx Pharmaceuticals, Inc.: DULoxetine DR USP</title>
    <link href="https://recalls.watch/recall/fda/95922/"/>
    <updated>2025-01-01T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: CGMP Deviations: the presence of a Nitrosamine Drug Substance Related Impurity (NDSRI), N-Nitroso-Duloxetine above the interim acceptable intake limit</summary>
  </entry>
  <entry>
    <id>https://recalls.watch/recall/fda/95900/</id>
    <title>RemedyRepack Inc.: Duloxetine Delayed-Release Capsules</title>
    <link href="https://recalls.watch/recall/fda/95900/"/>
    <updated>2025-01-01T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: CGMP Deviations; presence of N-nitroso-duloxetine impurity above recommended interim limit.</summary>
  </entry>
  <entry>
    <id>https://recalls.watch/recall/fda/95853/</id>
    <title>Breckenridge Pharmaceutical, Inc: Duloxetine Delayed-Release Capsules and 1 more</title>
    <link href="https://recalls.watch/recall/fda/95853/"/>
    <updated>2025-01-01T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: CGMP Deviations: presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.</summary>
  </entry>
  <entry>
    <id>https://recalls.watch/recall/fda/95849/</id>
    <title>Amerisource Health Services LLC: Duloxetine Delayed-Release Capsules and 2 more</title>
    <link href="https://recalls.watch/recall/fda/95849/"/>
    <updated>2024-12-11T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: CGMP Deviations: Presence of N-nitroso-duloxetine impurity above the recommended interim limit</summary>
  </entry>
  <entry>
    <id>https://recalls.watch/recall/fda/95756/</id>
    <title>Rising Pharma Holding, Inc.: Duloxetine Delayed-Release Capsules USP and 2 more</title>
    <link href="https://recalls.watch/recall/fda/95756/"/>
    <updated>2024-12-11T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: CGMP Deviations: Presence of N-nitroso-duloxetine impurity above recommended interim limit</summary>
  </entry>
  <entry>
    <id>https://recalls.watch/recall/fda/95508/</id>
    <title>Breckenridge Pharmaceutical, Inc: Duloxetine Delayed-Release Capsules</title>
    <link href="https://www.accessdata.fda.gov/scripts/ires/index.cfm?Event=95508"/>
    <updated>2024-10-23T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit</summary>
  </entry>
  <entry>
    <id>https://recalls.watch/recall/fda/94639/</id>
    <title>Golden State Medical Supply Inc.: Duloxetine Delayed-Release Capsules</title>
    <link href="https://www.accessdata.fda.gov/scripts/ires/index.cfm?Event=94639"/>
    <updated>2024-07-03T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-nitroso-duloxetine, above the proposed interim limit.</summary>
  </entry>
  <entry>
    <id>https://recalls.watch/recall/fda/94611/</id>
    <title>Breckenridge Pharmaceutical, Inc: Duloxetine Delayed-Release Capsules</title>
    <link href="https://www.accessdata.fda.gov/scripts/ires/index.cfm?Event=94611"/>
    <updated>2024-06-26T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit</summary>
  </entry>
  <entry>
    <id>https://recalls.watch/recall/fda/94648/</id>
    <title>Preferred Pharmaceuticals, Inc.: Duloxetine Delayed-Release Cap USP 30mg</title>
    <link href="https://www.accessdata.fda.gov/scripts/ires/index.cfm?Event=94648"/>
    <updated>2024-05-29T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit</summary>
  </entry>
  <entry>
    <id>https://recalls.watch/recall/fda/94483/</id>
    <title>Breckenridge Pharmaceutical, Inc: Duloxetine Delayed-Release Capsules and 2 more</title>
    <link href="https://www.accessdata.fda.gov/scripts/ires/index.cfm?Event=94483"/>
    <updated>2024-05-15T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit</summary>
  </entry>
</feed>
